Cargando…

A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most common malignancy of liver cancer. However, treatment of HCC is still severely limited due to limitation of drug therapy. We aimed to screen more possible target genes and candidate drugs for HCC, exploring the possibility of drug treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Meng, Shong, Koeun, Li, Xiangyu, Ashraf, Sajda, Shi, Mengnan, Kim, Woonghee, Nielsen, Jens, Turkez, Hasan, Shoaie, Saeed, Uhlen, Mathias, Zhang, Cheng, Mardinoglu, Adil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946504/
https://www.ncbi.nlm.nih.gov/pubmed/35326724
http://dx.doi.org/10.3390/cancers14061573
_version_ 1784674209198243840
author Yuan, Meng
Shong, Koeun
Li, Xiangyu
Ashraf, Sajda
Shi, Mengnan
Kim, Woonghee
Nielsen, Jens
Turkez, Hasan
Shoaie, Saeed
Uhlen, Mathias
Zhang, Cheng
Mardinoglu, Adil
author_facet Yuan, Meng
Shong, Koeun
Li, Xiangyu
Ashraf, Sajda
Shi, Mengnan
Kim, Woonghee
Nielsen, Jens
Turkez, Hasan
Shoaie, Saeed
Uhlen, Mathias
Zhang, Cheng
Mardinoglu, Adil
author_sort Yuan, Meng
collection PubMed
description SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most common malignancy of liver cancer. However, treatment of HCC is still severely limited due to limitation of drug therapy. We aimed to screen more possible target genes and candidate drugs for HCC, exploring the possibility of drug treatments from systems biological perspective. We identified ten candidate target genes, which are hub genes in HCC co-expression networks, which also possess significant prognostic value in two independent HCC cohorts. The rationality of these target genes was well demonstrated through variety analyses of patient expression profiles. We then screened candidate drugs for target genes and finally identified withaferin-a and mitoxantrone as the candidate drug for HCC treatment. The drug effectiveness was validated in in vitro model and computational analysis, providing more evidence for our drug repositioning method and results. ABSTRACT: Hepatocellular carcinoma (HCC) is a malignant liver cancer that continues to increase deaths worldwide owing to limited therapies and treatments. Computational drug repurposing is a promising strategy to discover potential indications of existing drugs. In this study, we present a systematic drug repositioning method based on comprehensive integration of molecular signatures in liver cancer tissue and cell lines. First, we identify robust prognostic genes and two gene co-expression modules enriched in unfavorable prognostic genes based on two independent HCC cohorts, which showed great consistency in functional and network topology. Then, we screen 10 genes as potential target genes for HCC on the bias of network topology analysis in these two modules. Further, we perform a drug repositioning method by integrating the shRNA and drug perturbation of liver cancer cell lines and identifying potential drugs for every target gene. Finally, we evaluate the effects of the candidate drugs through an in vitro model and observe that two identified drugs inhibited the protein levels of their corresponding target genes and cell migration, also showing great binding affinity in protein docking analysis. Our study demonstrates the usefulness and efficiency of network-based drug repositioning approach to discover potential drugs for cancer treatment and precision medicine approach.
format Online
Article
Text
id pubmed-8946504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89465042022-03-25 A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma Yuan, Meng Shong, Koeun Li, Xiangyu Ashraf, Sajda Shi, Mengnan Kim, Woonghee Nielsen, Jens Turkez, Hasan Shoaie, Saeed Uhlen, Mathias Zhang, Cheng Mardinoglu, Adil Cancers (Basel) Article SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most common malignancy of liver cancer. However, treatment of HCC is still severely limited due to limitation of drug therapy. We aimed to screen more possible target genes and candidate drugs for HCC, exploring the possibility of drug treatments from systems biological perspective. We identified ten candidate target genes, which are hub genes in HCC co-expression networks, which also possess significant prognostic value in two independent HCC cohorts. The rationality of these target genes was well demonstrated through variety analyses of patient expression profiles. We then screened candidate drugs for target genes and finally identified withaferin-a and mitoxantrone as the candidate drug for HCC treatment. The drug effectiveness was validated in in vitro model and computational analysis, providing more evidence for our drug repositioning method and results. ABSTRACT: Hepatocellular carcinoma (HCC) is a malignant liver cancer that continues to increase deaths worldwide owing to limited therapies and treatments. Computational drug repurposing is a promising strategy to discover potential indications of existing drugs. In this study, we present a systematic drug repositioning method based on comprehensive integration of molecular signatures in liver cancer tissue and cell lines. First, we identify robust prognostic genes and two gene co-expression modules enriched in unfavorable prognostic genes based on two independent HCC cohorts, which showed great consistency in functional and network topology. Then, we screen 10 genes as potential target genes for HCC on the bias of network topology analysis in these two modules. Further, we perform a drug repositioning method by integrating the shRNA and drug perturbation of liver cancer cell lines and identifying potential drugs for every target gene. Finally, we evaluate the effects of the candidate drugs through an in vitro model and observe that two identified drugs inhibited the protein levels of their corresponding target genes and cell migration, also showing great binding affinity in protein docking analysis. Our study demonstrates the usefulness and efficiency of network-based drug repositioning approach to discover potential drugs for cancer treatment and precision medicine approach. MDPI 2022-03-19 /pmc/articles/PMC8946504/ /pubmed/35326724 http://dx.doi.org/10.3390/cancers14061573 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yuan, Meng
Shong, Koeun
Li, Xiangyu
Ashraf, Sajda
Shi, Mengnan
Kim, Woonghee
Nielsen, Jens
Turkez, Hasan
Shoaie, Saeed
Uhlen, Mathias
Zhang, Cheng
Mardinoglu, Adil
A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
title A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
title_full A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
title_fullStr A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
title_full_unstemmed A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
title_short A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
title_sort gene co-expression network-based drug repositioning approach identifies candidates for treatment of hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946504/
https://www.ncbi.nlm.nih.gov/pubmed/35326724
http://dx.doi.org/10.3390/cancers14061573
work_keys_str_mv AT yuanmeng agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT shongkoeun agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT lixiangyu agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT ashrafsajda agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT shimengnan agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT kimwoonghee agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT nielsenjens agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT turkezhasan agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT shoaiesaeed agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT uhlenmathias agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT zhangcheng agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT mardinogluadil agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT yuanmeng genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT shongkoeun genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT lixiangyu genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT ashrafsajda genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT shimengnan genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT kimwoonghee genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT nielsenjens genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT turkezhasan genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT shoaiesaeed genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT uhlenmathias genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT zhangcheng genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma
AT mardinogluadil genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma